USFDA grants FTD to efanesoctocog alfa for hemophilia A treatment

By PBR Staff Writer

The U.S. Food and Drug Administration (FDA) has granted efanesoctocog alfa – earlier termed BIVV001 (rFVIIIFc-VWF-XTEN) – Fast Track Designation (FTD) for the treatment of patients suffering from hemophilia A.